Genmab — Maj 2019
-
ema variation procedure on the agenda this week, “Extension of indication to
extend the existing therapeutic indication for
Darzalex (daratumumab) in combination with
lenalidomide and dexamethasone (Rd) for the
treatment of adult patients with newly diagnosed
multiple myeloma who are ineligible forautologous stem cell transplant (ASCT)"
-
and “Extension of indication to
extend the existing therapeutic indication for
DARZALEX (daratumumab) in combination with
bortezomib, thalidomide and dexamethasone for
the treatment of adult patients with newly
diagnosed multiple myeloma who are eligible for
autologous stem cell transplant (ASCT)" -
Tror ikke der kommer mere angående denne ansøgning og ufatteligt at kursen falder på en ansøgning som ikke har nogen betydning for kursen. Virker som ren panik. I og med Genmab ikke har op eller nedjusteret guiding er konklusionen i min lille verden at årsguidingen er intakt og i så fald skal genmab ikke uddybe mere.
-
Hvis du ellers tror på 10 mia. dollar topsalgsestimat hvorfor så bekymrer sig om de her små bump. Genmab har annonceret en ansøgning og ydermere sagt at det ikke har beslutte noteringen om den skal gennemføres. Så det er vel fordi de ikke vil røbe hvad de har gang i p.t at der ikke bliver lukket mere ud.
-
1 spø. + 1 konstatering:
-
Skal vi længere ned de kommende dage (aht. fin suppleringsmulighed)?
-
Jeg synes det er fint med lidt mangel på (jubel)information ;-), selvom jeg godt ved det er noget information I efterlyser lige p.t.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
